Advanced

Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders

Smeland, S; Muller, C; Alvegård, Thor LU ; Wiklund, T; Wiebe, Thomas LU ; Bjork, O; Stenwig, AE; Willen, H; Holmstrom, T and Folleras, G, et al. (2003) In European Journal of Cancer 39(4). p.488-494
Abstract
From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume < 190 ml, 24-h serum methotrexate > 4.5 muM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this... (More)
From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume < 190 ml, 24-h serum methotrexate > 4.5 muM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in > 70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome. (C) 2003 Elsevier Science Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
prognosis, limb salvage, neo-adjuvant therapy, chemotherapy, osteosarcoma, clinical protocols, sex, Scandinavia
in
European Journal of Cancer
volume
39
issue
4
pages
488 - 494
publisher
IFAC & Elsevier Ltd.
external identifiers
  • pmid:12751380
  • wos:000181686800022
  • scopus:12244289913
ISSN
1879-0852
DOI
language
English
LU publication?
yes
id
bc2f9f66-f327-4910-bc8e-6c111dc98b5d (old id 315438)
date added to LUP
2007-09-22 10:56:48
date last changed
2018-06-10 03:46:40
@article{bc2f9f66-f327-4910-bc8e-6c111dc98b5d,
  abstract     = {From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume &lt; 190 ml, 24-h serum methotrexate &gt; 4.5 muM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in &gt; 70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome. (C) 2003 Elsevier Science Ltd. All rights reserved.},
  author       = {Smeland, S and Muller, C and Alvegård, Thor and Wiklund, T and Wiebe, Thomas and Bjork, O and Stenwig, AE and Willen, H and Holmstrom, T and Folleras, G and Brosjo, O and Kivioja, A and Jonsson, Kjell and Monge, O and Saeter, G},
  issn         = {1879-0852},
  keyword      = {prognosis,limb salvage,neo-adjuvant therapy,chemotherapy,osteosarcoma,clinical protocols,sex,Scandinavia},
  language     = {eng},
  number       = {4},
  pages        = {488--494},
  publisher    = {IFAC & Elsevier Ltd.},
  series       = {European Journal of Cancer},
  title        = {Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders},
  url          = {http://dx.doi.org/},
  volume       = {39},
  year         = {2003},
}